You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Dash Bio announced it raised $30 Million in an initial filing from an offering of $30 Million
PRIVATEJul 14, 2026•2 months ago
Amount Raised
$30 Million
Round Type
Venture - Series Unknown
BostonBiotechnology
Investors
Swift VenturesFreestyle CapitalOak Hc/Ft
Description
Dash Bio has raised $30 million in Series A financing to enhance infrastructure for next-generation medicine development. The round was led by Oak HC/FT, with participation from existing investors Freestyle Capital and Swift Ventures. This funding aims to streamline drug development processes that are often resource-intensive. Dash Bio is focused on modernizing the support infrastructure for drug development.
Company Information
Company
Dash Bio
Location
56 BROAD STREET
Boston, Massachusetts, United States
About
Dash Bio is revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Dash Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnology